title: Expression Status of UBE2Q2 in Colorectal Primary Tumors and Cell Lines.
abstract: BACKGROUND
  Activation of the ubiquitin-proteasome pathway in various malignancies, including colorectal cancer, is established. This pathway mediates the degradation of damaged proteins and regulates growth and stress response. The novel human gene, UBE2Q2, with a putative ubiquitin-conjugating enzyme activity, is reported to be overexpressed in some malignancies. We sought to investigate the expression levels of the UBE2Q2 gene in colorectal cell lines as well as in cancerous and normal tissues from patients with colorectal cancer.
  
  
  METHODS
  Levels of UBE2Q2 mRNA in cell lines were assessed by Real-Time PCR. Western blotting was employed to investigate the levels of the UBE2Q2 protein in 8 colorectal cell lines and 43 colorectal tumor samples.
  
  
  RESULTS
  Expression of UBE2Q2 was observed at the level of both mRNA and protein in colorectal cell lines, HT29/219, LS180, SW742, Caco2, HTC116, SW48, SW480, and SW1116. Increased levels of UBE2Q2 immunoreactivity was observed in the 65.11% (28 out of 43) of the colorectal carcinoma tissues when compared with their corresponding normal tissues. Difference between the mean intensities of UBE2Q2 bands from cancerous and normal tissues was statistically significant at P<0.001 (paired t test).
  
  
  CONCLUSIONS
  We showed the expression pattern of the novel human gene, UBE2Q2, in 8 colorectal cell lines. Overexpression of UBE2Q2 in the majority of the colorectal carcinoma samples denotes that it may have implications for the pathogenesis of colorectal cancer.
authors.affiliation: Department of Biochemistry-Recombinant Protein Laboratory, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;
authors.forename: Sayed Mohammad
authors.initials: SM
authors.lastname: Shafiee
authors.affiliation: Department of Biochemistry-Recombinant Protein Laboratory, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;
authors.forename: Atefeh
authors.initials: A
authors.lastname: Seghatoleslam
authors.affiliation: Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran;
authors.forename: Mohsen
authors.initials: M
authors.lastname: Nikseresht
authors.affiliation: Colorectal Research Center, Shahid Faghihi Hospital, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran;
authors.forename: Seyed Vahid
authors.initials: SV
authors.lastname: Hosseini
authors.affiliation: Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;
authors.forename: Mahvash
authors.initials: M
authors.lastname: Alizadeh-Naeeni
authors.affiliation: Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;
authors.forename: Akbar
authors.initials: A
authors.lastname: Safaei
authors.affiliation: Department of Biochemistry-Recombinant Protein Laboratory, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; ; Endocrine and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Ali Akbar
authors.initials: AA
authors.lastname: Owji
keywords: Cell Line; Colorectal Cancer; Gene Expression; UBE2Q2
references.citation: Cell. 1995 Apr 21;81(2):279-88
references.pmid: 7736580
references.citation: Biol Reprod. 2004 Feb;70(2):406-14
references.pmid: 14561654
references.citation: Biol Reprod. 2006 Sep;75(3):395-406
references.pmid: 16760379
references.citation: Cancer Res. 1984 Oct;44(10):4241-53
references.pmid: 6467184
references.citation: Nat Protoc. 2008;3(6):1101-8
references.pmid: 18546601
references.citation: Physiol Rev. 2002 Apr;82(2):373-428
references.pmid: 11917093
references.citation: Annu Rev Pathol. 2011;6:479-507
references.pmid: 21090969
references.citation: Cancer Treat Rev. 2003 May;29 Suppl 1:3-9
references.pmid: 12738238
references.citation: Arch Iran Med. 2012 Jun;15(6):352-5
references.pmid: 22642244
references.citation: Trends Biochem Sci. 2011 Jul;36(7):355-63
references.pmid: 21641804
references.citation: Tumour Biol. 2012 Jun;33(3):723-30
references.pmid: 22170434
references.citation: Biochem Biophys Res Commun. 2006 Jan 6;339(1):422-9
references.pmid: 16300736
references.citation: Curr Biol. 1996 Apr 1;6(4):455-66
references.pmid: 8723350
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4294-9
references.pmid: 8633058
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Biochim Biophys Acta. 2008 Dec;1782(12):800-8
references.pmid: 18619533
references.citation: Cancer Invest. 2007 Sep;25(6):502-13
references.pmid: 17882664
references.citation: Cancer Genet Cytogenet. 2010 Mar;197(2):101-6
references.pmid: 20193842
references.citation: J Cell Biochem Suppl. 2000;34:40-51
references.pmid: 10762014
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Eur J Cancer. 2004 Oct;40(15):2217-29
references.pmid: 15454246
references.citation: Cancer Res. 1976 Dec;36(12):4562-9
references.pmid: 1000501
references.citation: Cancer Res. 1989 Jun 1;49(11):2898-904
references.pmid: 2541895
references.citation: Oncogene. 2007 Oct 4;26(45):6509-17
references.pmid: 17471241
references.citation: Mol Cancer Res. 2009 Sep;7(9):1553-62
references.pmid: 19723876
references.citation: Int J Cancer. 1988 Feb 15;41(2):287-96
references.pmid: 3338874